Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.
Acute radiation syndrome
Approved pharmaceutical drugs
Granulocyte colony-stimulating factor
Radiation medical countermeasure
Romiplostim
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
03 08 2020
03 08 2020
Historique:
received:
09
06
2020
accepted:
28
07
2020
revised:
12
07
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
25
5
2021
Statut:
epublish
Résumé
It has been reported that the high-dosage administration of domestically approved pharmaceutical drugs, especially granulocyte colony-stimulating factor (G-CSF) and romiplostim (RP), is a rapid and appropriate medical treatment for preventing severe acute radiation syndrome (ARS) of victims exposed to lethal total-body irradiation (TBI). However, it remains unclear whether or not the clinical dosage administration of these drugs can ameliorate TBI-induced ARS and related high mortality in order to find various drug treatment options and less toxic optimum protocol depending on the situation surrounding the radiological accidents. We assessed the clinical dosage administration in combination with G-CSF and RP as intraperitoneal injection in C57BL/6 J mice exposed to more than 7-Gy lethal dose of X-ray TBI for the survival study evaluated by the log-rank test. Bone marrow and splenic cells were collected on the 21st day, when 1 week has passed from last administration, to detect the level of cell apoptosis, intracellular reactive oxygen species (ROS), and nuclear factor erythroid 2-related factor 2 (Nrf2)-related anti-oxidative gene expressions, and enzyme-linked immune sorbent assay using sera was performed for cell senescence and inflammation status analyzed with one-way ANOVA and Tukey-Kramer or Bonferroni/Dunn multiple comparison tests. The combined once-daily administration of 10 μg/kg G-CSF for 4 times and 10 μg/kg RP once a week for 3 times improve the 30-day survival rate of lethal TBI mice compared with untreated TBI mice, accompanied by a gradual increase in the body weight and hematopoietic cell numbers. The radio-mitigative effect is probably attributed to the scavenging of ROS and the reduction in cell apoptosis. These changes were associated with the upregulation of Nrf2 and its downstream anti-oxidative targets in TBI mice. Furthermore, this combination modulated TBI-induced cell senescence an d inflammation markers. This study suggested that the clinical dosage administration in combination with G-CSF and RP may also have radio-mitigative effects on mice exposed to lethal TBI and may be a potent therapeutic agent for mitigating radiation-induced severe ARS.
Sections du résumé
BACKGROUND
It has been reported that the high-dosage administration of domestically approved pharmaceutical drugs, especially granulocyte colony-stimulating factor (G-CSF) and romiplostim (RP), is a rapid and appropriate medical treatment for preventing severe acute radiation syndrome (ARS) of victims exposed to lethal total-body irradiation (TBI). However, it remains unclear whether or not the clinical dosage administration of these drugs can ameliorate TBI-induced ARS and related high mortality in order to find various drug treatment options and less toxic optimum protocol depending on the situation surrounding the radiological accidents.
METHODS
We assessed the clinical dosage administration in combination with G-CSF and RP as intraperitoneal injection in C57BL/6 J mice exposed to more than 7-Gy lethal dose of X-ray TBI for the survival study evaluated by the log-rank test. Bone marrow and splenic cells were collected on the 21st day, when 1 week has passed from last administration, to detect the level of cell apoptosis, intracellular reactive oxygen species (ROS), and nuclear factor erythroid 2-related factor 2 (Nrf2)-related anti-oxidative gene expressions, and enzyme-linked immune sorbent assay using sera was performed for cell senescence and inflammation status analyzed with one-way ANOVA and Tukey-Kramer or Bonferroni/Dunn multiple comparison tests.
RESULTS
The combined once-daily administration of 10 μg/kg G-CSF for 4 times and 10 μg/kg RP once a week for 3 times improve the 30-day survival rate of lethal TBI mice compared with untreated TBI mice, accompanied by a gradual increase in the body weight and hematopoietic cell numbers. The radio-mitigative effect is probably attributed to the scavenging of ROS and the reduction in cell apoptosis. These changes were associated with the upregulation of Nrf2 and its downstream anti-oxidative targets in TBI mice. Furthermore, this combination modulated TBI-induced cell senescence an d inflammation markers.
CONCLUSIONS
This study suggested that the clinical dosage administration in combination with G-CSF and RP may also have radio-mitigative effects on mice exposed to lethal TBI and may be a potent therapeutic agent for mitigating radiation-induced severe ARS.
Identifiants
pubmed: 32746943
doi: 10.1186/s13287-020-01861-x
pii: 10.1186/s13287-020-01861-x
pmc: PMC7398212
doi:
Substances chimiques
Receptors, Fc
0
Recombinant Fusion Proteins
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Thrombopoietin
9014-42-0
romiplostim
GN5XU2DXKV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Références
Free Radic Res. 2019 Aug;53(8):851-864
pubmed: 31234659
Oncotarget. 2016 Nov 8;7(45):72443-72457
pubmed: 27736799
Cell Physiol Biochem. 2015;36(5):2063-71
pubmed: 26202365
Biol Pharm Bull. 2010;33(1):29-34
pubmed: 20045931
Sci Rep. 2018 Jul 13;8(1):10659
pubmed: 30006622
Int Immunopharmacol. 2007 Apr;7(4):500-5
pubmed: 17321473
Free Radic Biol Med. 2019 May 20;136:60-75
pubmed: 30926566
Free Radic Biol Med. 2019 Dec;145:223-236
pubmed: 31580946
Int J Hematol. 2016 Jan;103(1):44-52
pubmed: 26511480
Blood. 2014 Jan 23;123(4):509-19
pubmed: 24184684
Oncogene. 2003 Sep 1;22(37):5734-54
pubmed: 12947383
Phys Med. 2016 Jan;32(1):150-61
pubmed: 26526749
Cytokine. 2015 Jan;71(1):22-37
pubmed: 25215458
Curr Pharm Biotechnol. 2015;17(2):190-9
pubmed: 26306743
Environ Toxicol. 2019 Jul;34(7):788-795
pubmed: 30843661
Future Oncol. 2014 Dec;10(15):2345-57
pubmed: 25525844
Nat Commun. 2016 Dec 14;7:13593
pubmed: 27966538
Int J Radiat Biol. 2017 Sep;93(9):870-884
pubmed: 28657406
Free Radic Biol Med. 2017 Dec;113:59-70
pubmed: 28939421
J Radiat Res. 2005 Dec;46(4):425-33
pubmed: 16394633
Cell Stem Cell. 2013 Jan 3;12(1):37-48
pubmed: 23246483
Drugs. 2011 Apr 16;71(6):679-707
pubmed: 21504247
Free Radic Biol Med. 1999 Nov;27(9-10):922-35
pubmed: 10569625
Blood. 2014 May 15;123(20):3105-15
pubmed: 24622326
Int J Radiat Biol. 2017 Sep;93(9):851-869
pubmed: 28650707
Radiat Res. 2018 Nov;190(5):449-463
pubmed: 30070965
Mutat Res Genet Toxicol Environ Mutagen. 2016 Jan 1;795:36-40
pubmed: 26774665
FEBS J. 2017 Apr;284(8):1233-1245
pubmed: 28236663
Nature. 2015 Nov 26;527(7579):466-471
pubmed: 26570997
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Blood. 2017 Oct 26;130(17):1923-1933
pubmed: 28864815
In Vivo. 2008 May-Jun;22(3):305-9
pubmed: 18610740
Exp Gerontol. 2004 Nov-Dec;39(11-12):1751-9
pubmed: 15582292
Sci Rep. 2020 Feb 4;10(1):1757
pubmed: 32019942
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12052-7
pubmed: 22778398
Physiol Res. 2002;51(5):511-21
pubmed: 12470204
FEBS Lett. 2008 Mar 19;582(6):925-30
pubmed: 18294966
Int J Radiat Biol. 2017 Sep;93(9):885-906
pubmed: 28657400
Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Oct;50(4):573-94
pubmed: 3531055
Vascul Pharmacol. 2016 Dec;87:150-158
pubmed: 27650166
Int J Radiat Biol. 2018 Feb;94(2):114-123
pubmed: 29251085
Nat Rev Cancer. 2006 Sep;6(9):702-13
pubmed: 16929324
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567